JP2021501151A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501151A5
JP2021501151A5 JP2020523324A JP2020523324A JP2021501151A5 JP 2021501151 A5 JP2021501151 A5 JP 2021501151A5 JP 2020523324 A JP2020523324 A JP 2020523324A JP 2020523324 A JP2020523324 A JP 2020523324A JP 2021501151 A5 JP2021501151 A5 JP 2021501151A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
atopic dermatitis
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523324A
Other languages
English (en)
Japanese (ja)
Other versions
JP7218364B2 (ja
JP2021501151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/057682 external-priority patent/WO2019084383A1/en
Publication of JP2021501151A publication Critical patent/JP2021501151A/ja
Publication of JP2021501151A5 publication Critical patent/JP2021501151A5/ja
Application granted granted Critical
Publication of JP7218364B2 publication Critical patent/JP7218364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523324A 2017-10-27 2018-10-26 Jakキナーゼ阻害剤としてのピリミジン化合物 Active JP7218364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
US62/577,852 2017-10-27
PCT/US2018/057682 WO2019084383A1 (en) 2017-10-27 2018-10-26 PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Publications (3)

Publication Number Publication Date
JP2021501151A JP2021501151A (ja) 2021-01-14
JP2021501151A5 true JP2021501151A5 (enExample) 2021-09-30
JP7218364B2 JP7218364B2 (ja) 2023-02-06

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523324A Active JP7218364B2 (ja) 2017-10-27 2018-10-26 Jakキナーゼ阻害剤としてのピリミジン化合物

Country Status (38)

Country Link
US (7) US10308646B2 (enExample)
EP (1) EP3672965B1 (enExample)
JP (1) JP7218364B2 (enExample)
KR (1) KR102613503B1 (enExample)
CN (1) CN111247142B (enExample)
AR (1) AR113803A1 (enExample)
AU (1) AU2018354370B2 (enExample)
BR (1) BR112020008015A2 (enExample)
CA (1) CA3074034A1 (enExample)
CL (1) CL2020001090A1 (enExample)
CR (1) CR20200180A (enExample)
CU (1) CU24671B1 (enExample)
DK (1) DK3672965T3 (enExample)
DO (1) DOP2020000083A (enExample)
EA (1) EA202091016A1 (enExample)
EC (1) ECSP20023795A (enExample)
ES (1) ES2932526T3 (enExample)
GE (2) GEP20227344B (enExample)
HR (1) HRP20221221T1 (enExample)
HU (1) HUE060401T2 (enExample)
IL (1) IL274037B2 (enExample)
LT (1) LT3672965T (enExample)
MA (1) MA49956B1 (enExample)
MD (1) MD3672965T2 (enExample)
MX (1) MX2020004255A (enExample)
NI (1) NI202000032A (enExample)
PE (1) PE20201495A1 (enExample)
PH (1) PH12020500528A1 (enExample)
PL (1) PL3672965T3 (enExample)
PT (1) PT3672965T (enExample)
RS (1) RS63608B1 (enExample)
SG (1) SG11202001706RA (enExample)
SI (1) SI3672965T1 (enExample)
SM (1) SMT202200409T1 (enExample)
TW (1) TWI789446B (enExample)
UA (1) UA125130C2 (enExample)
WO (1) WO2019084383A1 (enExample)
ZA (1) ZA202001641B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200409T1 (it) 2017-10-27 2022-11-18 Theravance Biopharma R&D Ip Llc Composto di pirimidina come inibitore di chinasi jak
CA3121408A1 (en) * 2018-11-30 2020-06-04 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
TW202106681A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
WO2020219639A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as jak kinase inhibitors
MX2023001259A (es) * 2020-07-28 2023-05-15 Arcutis Biotherapeutics Inc Formulaciones tópicas que contienen inhibidor de jak y laureth-4.
MX2023002378A (es) * 2020-08-26 2023-05-22 Nalo Therapeutics Moduladores de proteinas de la familia de protooncogenes myc.
WO2022076771A1 (en) * 2020-10-08 2022-04-14 Icahn School Of Medicine At Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療fxr誘發之搔癢之il-31調節劑
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス, インコーポレイテッド Tyk2分解剤およびそれらの使用
JP2024544404A (ja) 2021-12-15 2024-11-29 アーキュティス・バイオセラピューティクス・インコーポレーテッド Shr0302の安定な製剤
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
DE60128709T2 (de) 2000-09-15 2007-12-27 Vertex Pharmaceuticals Inc., Cambridge Triazol-verbindungen als protein-kinase-inhibitoren
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526468A (en) 2000-12-21 2004-03-26 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
DE602006021776D1 (de) 2005-11-16 2011-06-16 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
EP2044063A1 (en) 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
KR20140103972A (ko) 2011-12-22 2014-08-27 에프. 호프만-라 로슈 아게 세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (enExample) * 2014-08-21 2018-03-31
CN106687467A (zh) * 2014-09-30 2017-05-17 韩美精密化学株式会社 高纯度(r)‑9‑[2‑(磷酰甲氧基)丙基]腺嘌呤的制备方法
EP3303348B1 (en) * 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
SMT202200409T1 (it) * 2017-10-27 2022-11-18 Theravance Biopharma R&D Ip Llc Composto di pirimidina come inibitore di chinasi jak
TW202106681A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
WO2020219639A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as jak kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2021501151A5 (enExample)
HU225852B1 (en) Pyrazine derivatives, process for producing them, pharmaceutical compositions containing them and their use
JP2013514356A (ja) ピロロ[2,3−d]ピリミジン化合物
IL274037B2 (en) A pyrimidine compound as a JAK kinase inhibitor
CA2540768A1 (en) Pyrazolo and imidazo-pyrimidine derivatives
JP2010132669A (ja) ストロンチウムラネレートのアルファー(α)−結晶形、その製造方法、及びそれを含む医薬組成物
CN110092787A (zh) 一种化合物或其药用盐或组合物的制备及应用
JP6673218B2 (ja) ジヒドロナフタレン誘導体
JP2015516968A5 (enExample)
TW202208336A (zh) Enpp1調節劑及其用途
JP2017533237A (ja) 強力なγ−セクレターゼモジュレータ
EP3458440B1 (en) Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
WO2014151682A1 (en) Pyrimidine compounds as kinase inhibitors
MX2025001439A (es) Dímeros de 3-etilamino-indol como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos
CN117062819A (zh) 多环化合物及其用途
EA003941B1 (ru) 2-аминопиридины, содержащие конденсированные кольца в качестве заместителей
AU2014252281A1 (en) Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agents
JP7165501B2 (ja) 新規ベンズイミダゾール化合物からなる医薬
TW201206910A (en) Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
JP2023550473A (ja) 小分子化合物および組成物
JP7175878B2 (ja) 新規ベンズイミダゾロン化合物およびその医薬用途
JP2014189499A (ja) 新規なピリミジンヌクレオシドのシリル誘導体
JP2011102241A (ja) 新規1−アミノカルボニルピペリジン誘導体
JPWO2009048123A1 (ja) ビス(トリメチルシリル)フェニル化合物又はその塩、及びその用途
CA3020239C (en) Processes for preparing oxathiazin-like compounds